George Carlo: Microwave News Article Archive (2004 - )

Steve Cleary, whose career in microwave research spanned from the military’s Tri-Service program in the late 1950s to the cell phone industry’s sham project in the 1990s, died at home on June 7 of a heart attack. He leaves his wife, Fran, four daughters and ten grandchildren. He was 79.

Cleary was a professor of biophysics at Virginia Commonwealth University (VCU) in Richmond from 1964 to 2002. Like many other radiobiologists of his generation, he was trained at the University of Rochester. He later got his PhD at New York University under Merril Eisenbud, a former senior health official at the Atomic Energy Commission. Cleary’s doctoral thesis was the first epidemiological study of the impact of microwaves on the eyes. He detected a significant increase in the incidence of defects in the lenses of military personnel who had long-term exposure, a rare published report of an adverse finding.

Nobody ever went broke underestimating the intelligence of the American public, H.L. Mencken, the American journalist, famously said years ago. And so it continues today, not only in the U.S. but most everywhere else. The continuing EMF controversy, stimulated by three new books —Sam Milham’s Dirty Electricity, Devra Davis’s Disconnect and Ann Gittleman’s Zapped— has fueled the demand for quick fixes. (None of these authors recommends them.) Just about every day, someone contacts us, pitching a new product or, on the consumer side, asking if they do any good.

After sidestepping the cell phone health controversy for many years, the FDA announced yesterday that it had asked the National Academy of Sciences (NAS) to hold a symposium and to advise what additional research needs to be done. It's déjà vu all over again. This is the same do-nothing strategy that George Carlo so successfully pursued for the CTIA, the wireless trade association, in the 1990s to make sure that very little health research got done. Over a six-year period, Carlo held meetings and wrote literature reviews. In the end, he spent $25 million of CTIA's money and had practically nothing to show for it. Neither Carlo nor the CTIA has ever accounted for where all that money went. Now, the CTIA and the FDA are planning to replay the same charade, albeit on a much smaller scale.